Top story

Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 31, 2025-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and...

Read full story

FDA Approves Contepo (fosfomycin) for Injection for the Treatment of Complicated Urinary Tract Infections

Drugs.com - New Drug Approvals
Wed, 22 Oct 2025
Read more

Sentynl Therapeutics Updates On Its NDA for CUTX-101

Drugs.com - New Drug Applications
Wed, 01 Oct 2025
Read more

FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

Drugs.com - New Drug Applications
Wed, 10 Sep 2025
Read more

Ascelia Pharma Submits Orviglance New Drug Application to the U.S. Food and Drug Administration

Drugs.com - New Drug Applications
Wed, 03 Sep 2025
Read more

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

Drugs.com - New Drug Applications
Wed, 03 Sep 2025
Read more

FDA Accepts Shionogi’s Ensitrelvir NDA for Review as the First Oral Therapy for the Prevention of COVID-19 Following Exposure

Drugs.com - New Drug Applications
Wed, 03 Sep 2025
Read more

Pfizer and BioNTech’s Comirnaty Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

Drugs.com - New Drug Approvals
Wed, 27 Aug 2025
Read more

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2

Drugs.com - New Drug Approvals
Wed, 27 Aug 2025
Read more

Travere Therapeutics Announces U.S. FDA Approves REMS Modification for Filspari (sparsentan) in IgA Nephropathy

Drugs.com - New Drug Approvals
Wed, 27 Aug 2025
Read more